Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 9/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 9/20 | 0.38 |
| ▸ | ADK | P55263 | 7/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19343833 | 0.88 | ADK (0.52) | ADKPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL19343826 | 0.88 | ADK (0.52) | ADKSLC29A1 | |
| SCHEMBL18009746 | 0.84 | ADK (0.40) | PRMT5WDR77ADKRXFP1PI4KA | |
| SCHEMBL18026249 | 0.82 | PI4KA (0.44) | PRMT5WDR77ADKRXFP1PI4KA | |
| SCHEMBL18009754 | 0.81 | PI4KA (0.55) | ADKRXFP1PI4KAPI4K2BPI4K2A | |
| SCHEMBL18535300 | 0.81 | PI4KA (0.55) | ADKRXFP1PI4KAPI4K2BPI4K2A | |
| SCHEMBL18009946 | 0.80 | PRMT5 (0.40) | PRMT5WDR77ADKPI4KAPI4K2B | |
| SCHEMBL1801068 | 0.80 | PI4KA (0.50) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5510441 | 0.80 | PI4KA (0.50) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL12546290 | 0.80 | PI4KA (0.50) | RXFP1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 133/4885ADK 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.